Systematic Review on Therapeutic Applications of Yeast 'Saccharomyces'

Authors

  • Olivia Mondal  School of Applied and Interdisciplinary Sciences, Indian Association for the Cultivation of Sciences, Jadavpur, Kolkata, India
  • Devanshi Khanna  Clinical Research Department, School of Biosciences (SBS), Apeejay Stya University, Palwal- Sohna Road, Gurugram, India
  • Shalja Panwar  Centre of Excellence Laboratory, Department of Biochemistry and Plant Physiology, College of Biotechnology, Sardar Vallabhbhai Patel University of Agriculture & Technology, Meerut, India 4Department of Zoology, HNB Garhwal University, Uttarakhand, India
  • Shilpa Negi  Department of Biotechnology, SRM University, SRM Nagar, Kattankulathur, India
  • Sneha Basu  Department of Biotechnology, SRM University, SRM Nagar, Kattankulathur, India

DOI:

https://doi.org//10.32628/IJSRST218226

Keywords:

Probiotic, Recombinant Yeast, Intestinal disorders, Immunomodulation, Vaginal Infections

Abstract

This article is an examination of the therapeutic applications of yeast ‘Saccharomyces’. The scientific development and subsequent usage of Saccharomyces as a potential biodrug continue to influence researchers worldwide today. This article examines the research done and published by researchers and scientists. Consideration of current trends and data in scientific queries and demonstrates further aspects of therapeutic applications of yeast ‘Saccharomyces’. Additionally, this article explores options for the treatment of various ailments by using Saccharomyces as a probiotic. Being a probiotic, Saccharomyces has antimicrobial activity, can modulate immune responses and competes with pathogens for adhesion sites and nutrients. It showed efficient results and can be used in diarrhea, acute and chronic gastrointestinal diseases, Acute necrotizing pancreatitis (ANP), Giardiasis, Autoimmune Encephalomyelitis (EAE), Crohn's disease, etc. It is also proved to reduced the vaginal bacterial and fungal loads, thereby aiding the treatment of vaginal diseases; even oral administration has been tested to show positive results.

References

  1. Buts, J. P., Bernasconi, P., Van Craynest, M. P., Maldague, P. & Meyer, R. Response of human and rat small intestinal mucosa to oral administration of saccharomyces boulardii. Pediatr. Res. 20, (1986).
  2. Guslandi, M., Mezzi, G., Sorghi, M. & Testoni, P. A. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig. Dis. Sci. 45, (2000).
  3. Qamar, A. et al. Saccharomyces boulardii stimulates intestinal immunoglobulin a immune response to Clostridium difficile toxin A in mice. Infect. Immun. 69, (2001).
  4. Czerucka, D. & Rampal, P. Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes and Infection vol. 4 (2002).
  5. Blanquet, S., Meunier, J. P., Minekus, M., Marol-Bonnin, S. & Alric, M. Recombinant Saccharomyces cerevisiae expressing P450 in artificial digestive systems: A model for biodetoxication in the human digestive environment. Appl. Environ. Microbiol. 69, (2003).
  6. Mansour-Ghanaei, F., Dehbashi, N., Yazdanparast, K. & Shafaghi, A. Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis. World J. Gastroenterol. 9, (2003).
  7. Geyik, M. F. et al. The effects of Saccharomyces boulardii on bacterial translocation in rats with obstructive jaundice. Ann. R. Coll. Surg. Engl. 88, (2006).
  8. Garrait, G., Jarrige, J. F., Blanquet, S., Beyssac, E. & Alric, M. Recombinant Saccharomyces cerevisiae strain expressing a model cytochrome P450 in the rat digestive environment: Viability and bioconversion activity. Appl. Environ. Microbiol. 73, (2007).
  9. ?ahin, T. et al. Effects of the probiotic agent Saccharomyces Boulardii on the DNA damage in acute necrotizing pancreatitis induced rats. Hum. Exp. Toxicol. 26, (2007).
  10. Ardiani, A., Higgins, J. P. & Hodge, J. W. Vaccines based on whole recombinant Saccharomyces cerevisiae cells. FEMS Yeast Research vol. 10 (2010).
  11. Matuo, R. et al. Saccharomyces cerevisiae as a model system to study the response to anticancer agents. Cancer Chemotherapy and Pharmacology vol. 70 (2012).
  12. Kelesidis, T. & Pothoulakis, C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therapeutic Advances in Gastroenterology vol. 5 (2012).
  13. Feizizadeh, S., Salehi-Abargouei, A. & Akbari, V. Efficacy and safety of Saccharomyces boulardii for acute diarrhea. Pediatrics vol. 134 (2014).
  14. Hancox, L. R. et al. Effect of a single dose of Saccharomyces cerevisiae var. boulardii on the occurrence of porcine neonatal diarrhoea. Animal 9, (2015).
  15. Moré, M. I. & Swidsinski, A. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - A review. Clinical and Experimental Gastroenterology vol. 8 (2015).
  16. Rizzetto, L. et al. Fungal chitin induces trained immunity in human monocytes during cross-talk of the host with Saccharomyces cerevisiae. J. Biol. Chem. 291, (2016).
  17. West, C., Stanisz, A. M., Wong, A. & Kunze, W. A. Effects of Saccharomyces cerevisiae or boulardii yeasts on acute stress induced intestinal dysmotility. World J. Gastroenterol. 22, (2016).
  18. Zhang, Z., Wu, X., Cao, L., Zhong, Z. & Zhou, Y. Generation of glucagon-like peptide-2-expressing Saccharomyces cerevisiae and its improvement of the intestinal health of weaned rats. Microb. Biotechnol. 9, (2016).
  19. Hudson, L. E. et al. Characterization of the probiotic yeast Saccharomyces boulardii in the healthy mucosal immune system. PLoS One 11, (2016).
  20. Kwatra, B. Tinospora Crispa As A Future Cure For Obesity/Cholesterol. Int. J. Sci. Technol. Res. 6, 340–341 (2017).
  21. Kwatra, B. HACKING THE BLOOD-BRAIN BARRIER. Eur. J. Biol. Med. Sci. Res. 5, 10–13 (2017).
  22. Kwatra, B. LOCATOR THEORY FOR ELE-MENTS IN PERIODIC TABLE ‘LEPT’. Glob. J. Pure Appl. Chem. Res. 5, 9–10 (2017).
  23. Cayzeele-Decherf, A. et al. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. World J. Gastroenterol. 23, (2017).
  24. Srinivas, B. et al. Evaluating the probiotic and therapeutic potentials of Saccharomyces cerevisiae strain (OBS2) isolated from fermented nectar of toddy palm. AMB Express 7, (2017).
  25. Fakruddin, M., Hossain, M. N. & Ahmed, M. M. Antimicrobial and antioxidant activities of Saccharomyces cerevisiae IFST062013, a potential probiotic. BMC Complement. Altern. Med. 17, (2017).
  26. Appel-da-Silva, M. C., Narvaez, G. A., Perez, L. R. R., Drehmer, L. & Lewgoy, J. Saccharomyces cerevisiae var. boulardii fungemia following probiotic treatment. Med. Mycol. Case Rep. 18, (2017).
  27. Yu, L. et al. Saccharomyces boulardii Administration Changes Gut Microbiota and Attenuates D-Galactosamine-Induced Liver Injury. Sci. Rep. 7, (2017).
  28. Duman-Scheel, M. Saccharomyces cerevisiae (Baker’s Yeast) as an Interfering RNA Expression and Delivery System. Curr. Drug Targets 20, (2018).
  29. Nandy, S. K. & Srivastava, R. K. A review on sustainable yeast biotechnological processes and applications. Microbiological Research vol. 207 (2018).
  30. Kwatra, B. Bioactive-Compounds: alternative to control Candida spp. Int. J. Sci. Res. Rev. 8, 221–223 (2019).
  31. Kwatra, B. HYDROQUINONE: A novel growth inhibitor and apoptosis inducer in U-251 MG CELLS. Int. J. Med. Biomed. Stud. 3, 15–16 (2019).
  32. Kwatra, B. Allicin-An After Digestion Antimicrobial Agent. ACTA Sci. Microbiol. 2, 48–51 (2019).
  33. Kwatra, B. Effects of Mineral Separation by Time and Enteric Coating Mechanism for Calcium and Iron Absorption in Mammalia. Int. J. Sci. Res. 8, 1265–1270 (2019).
  34. Kwatra, B. MECHANISMS OF PATTERN FORMATION OF FBP17 IN MAST CELLS. Int. J. Adv. Res. 7, 413–414 (2019).
  35. Kwatra, B. Procuring Natural Dye for Solar Cell Using Leaf Waste. Int. J. Sci. Eng. Res. 7, 46–47 (2019).
  36. Kwatra, B. EXPRESSION AND CHARACTERIZATION IN PICHIA PASTORIS BY CLONING OF DELTA 4 DESATURASE FROM ISOCHRYSIS GALBANA. Indian J. Appl. Res. 9, 1–2 (2019).
  37. Kwatra, B. Holothuroidea (Sea Cucumber): Key to Anti-Aging. Int. J. Sci. Res. 8, 884 (2019).
  38. Kwatra, B. A REVIEW ON POTENTIAL PROPERTIES AND THERAPEUTIC APPLICATIONS OF BROMELAIN. www.wjpps.com 8, 488–500 (2019).
  39. Kwatra, B. A Review on Potential Properties and Therapeutic Applications of DHA and EPA. ijppr.humanjournals 16, 140–176 (2019).
  40. Kwatra, B. THE SIMVASTATIN AND DMXAA ON THE CO-CULTURE OF B16.F10 MELANOMA CELLS AND MACROPHAGES SHOWS ANTITUMOR ACTIVITY. World J. Pharm. Res. 8, 1318–1319 (2019).
  41. Czerucka, D. & Rampal, P. Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. World J. Gastroenterol. 25, (2019).
  42. Kumar, R. & Kumar, P. Yeast-based vaccines: New perspective in vaccine development and application. FEMS Yeast Research vol. 19 (2019).
  43. Kwatra, B. A REVIEW ON POTENTIAL PROPERTIES AND THERAPEUTIC APPLICATIONS OF LYCOPENE. Int. J. Med. Biomed. Stud. 4, 33–44 (2020).
  44. Kwatra, B. Candidate genes of OCD interacts with human retrovirus to form new link in inflammatory hypothesis. Int. J. Sci. Appl. Res. 7, 1–2 (2020).
  45. Kwatra, B. Maprovit 3, 6, 9: Perfect Companion of your Immune System to Fight Corona Virus Hit. Int. J. Sci. Res. 9, 241 (2020).
  46. Kwatra, B. A Review on Potential Properties and Therapeutic Applications of Vitamin D. Int. J. Sci. Res. 9, 682–691 (2020).
  47. Kwatra, B. COLLAGEN SUPPLEMENTATION?: THERAPY FOR SKIN DISORDERS?: A REVIEW. World J. Pharm. Res. 9, 2504–2518 (2020).
  48. Kwatra, B. A REVIEW ON POTENTIAL PROPERTIES AND THERAPEUTIC APPLICATIONS OF BRANCHED CHAIN AMINO. WORLD J. Pharm. Pharm. Sci. 9, 561–588 (2020).
  49. Kwatra, B. COLLAGEN SUPPLEMENTATION?: THERAPY FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS AND OSTEOARTHRITIS?: A REVIEW. WORLD J. Pharm. Pharm. Sci. 9, 589–604 (2020).
  50. Kwatra, B. A REVIEW ON POTENTIAL PROPERTIES AND THERAPEUTIC APPLICATIONS OF GRAPE SEED EXTRACT. World J. Pharm. Res. 9, 2519–2540 (2020).
  51. Kwatra, B. Studies on People Employed in High Risk Workplace?: Between Genetic Polymorphism for Tumor Necrosis Factor ( TNF- Α ) and Blood Pressure. Int. J. Innov. Res. Technol. 6, 268–270 (2020).
  52. Decherf, A. et al. Recovery of saccharomyces cerevisiae CNCM i-3856 in vaginal samples of healthy women after oral administration. Nutrients 12, (2020).
  53. de Campos Fraga-Silva, T. F. et al. Selenization of S. cerevisiae increases its protective potential in experimental autoimmune encephalomyelitis by triggering an intestinal immunomodulatory loop. Sci. Rep. 10, (2020).
  54. Del Rivero, J. et al. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. Front. Endocrinol. (Lausanne). 11, (2020).
  55. Wang, B. et al. Saccharomyces boulardii attenuates inflammatory response induced by Clostridium perfringens via TLR4/TLR15-MyD8 pathway in HD11 avian macrophages. Poult. Sci. 99, (2020).
  56. Ka?mierczak-Siedlecka, K., Ruszkowski, J., Fic, M., Folwarski, M. & Makarewicz, W. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases. Current Microbiology vol. 77 (2020).
  57. Pais, P., Almeida, V., Y?lmaz, M. & Teixeira, M. C. Saccharomyces boulardii: What makes it tick as successful probiotic? Journal of Fungi vol. 6 (2020).
  58. Gaziano, R., Sabbatini, S., Roselletti, E., Perito, S. & Monari, C. Saccharomyces cerevisiae-Based Probiotics as Novel Antimicrobial Agents to Prevent and Treat Vaginal Infections. Frontiers in Microbiology vol. 11 (2020).
  59. Constante, M. et al. Saccharomyces boulardii CNCM I-745 modulates the microbiota–gut–brain axis in a humanized mouse model of Irritable Bowel Syndrome. Neurogastroenterol. Motil. (2020) doi:10.1111/nmo.13985.
  60. Ribeiro, M. R. S. et al. Saccharomyces boulardii as therapeutic alternative in experimental giardiasis. J. Appl. Microbiol. (2020) doi:10.1111/jam.14941.

International Journal of Scientific Research in Science and Technology

Downloads

Published

2021-04-30

Issue

Volume 8, Issue 2, March-April-2021

Section

Research Articles

License

Copyright (c) IJSRST

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
Olivia Mondal, Devanshi Khanna, Shalja Panwar, Shilpa Negi, Sneha Basu, " Systematic Review on Therapeutic Applications of Yeast 'Saccharomyces', International Journal of Scientific Research in Science and Technology(IJSRST), Online ISSN : 2395-602X, Print ISSN : 2395-6011, Volume 8, Issue 2, pp.174-197, March-April-2021. Available at doi : https://doi.org/10.32628/IJSRST218226